Opendata, web and dolomites

EyeTREAT SIGNED

Innovative tool for personalized treatment of patients with neovascular age-macular degeneration: dosage optimization for long term efficacy treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EyeTREAT project word cloud

Explore the words cloud of the EyeTREAT project. It provides you a very rough idea of what is the project "EyeTREAT" about.

varies    lucentis    individualized    vitreous    avastin    benefit    expertise    reducing    instance    inter    with    amd    age    quality    ageing    optimization    vegf    tools    central    injection    computational    centre    tool    disciplinary    combining    manchester    clear    frequency    patients    definitely    eye    researcher    population    dosing    candidate    clinics    regular    eylea    invasively    personalization    individual    drug    burden    consists    effect    visual    2040    threatening    career    pharmacodynamic    first    health    sectoral    pioneer    patient    constitute    degeneration    ophthalmic    injections    missing    treatment    intravitreal    pharmacokinetic    therapeutic    efficient    dose    imaging    coherence    tomography    rest    regimen    appropriate    care    models    technique    25    clinical    ocular    scan    lasting    anticipated    measuring    character    retina    europeans    anti    million    ball    university    linking    treatments    thickness    renowned    quantitative    intervals    illnesses    macular    consensus    life    oct    optical    determinations    almost   

Project "EyeTREAT" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF MANCHESTER 

Organization address
address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL
website: www.manchester.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.research.manchester.ac.uk/portal/evamaria.delamo.html
 Total cost 122˙159 €
 EC max contribution 122˙159 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) coordinator 122˙159.00

Map

 Project objective

With the ageing population, visual threatening illnesses are increasing. For instance, age-related macular degeneration (AMD) is expected to affect almost 25 million Europeans by 2040. The AMD treatment consists in regular injections of the anti-VEGF therapeutic drug (Lucentis, Avastin, Eylea) into the eye ball, vitreous, for the rest of the patient life. However, the dosing intervals varies widely among the patients and there is no a clear consensus or quantitative method for evaluating the injection frequency. For that, computational tools linking the drug dose regimen and the drug effect in the retina are needed. However, such pharmacokinetic-pharmacodynamic models are still missing. Combining population pharmacokinetic and optical coherence tomography (OCT) imaging technique is a new, novel and promising approach. The drug effect can be evaluated non-invasively, measuring the central macular thickness in the retina scan. The models generated will allow appropriate individualized dosing regimen to the patients in clinics that will be anticipated from individual retina scan determinations with OCT. The optimization and personalization of dosing regimen will ensure an efficient long-lasting treatment, improving patient quality of life while reducing the burden to the health care system. Moreover, the models will increase our understanding in the treatments, constitute a pioneer tool in effect assessment in ocular therapeutic field and a first step towards more advanced ophthalmic models. The candidate has strong expertise in intravitreal pharmacokinetic and this project will advance her into clinical pharmacodynamic modelling at the renowned Centre for Applied Pharmacokinetic Research, University of Manchester. The inter-disciplinary and inter-sectoral character of the project will definitely benefit her career development as a researcher.

 Publications

year authors and title journal last update
List of publications.
2019 Astrid Subrizi, Eva M. del Amo, Viktor Korzhikov-Vlakh, Tatiana Tennikova, Marika Ruponen, Arto Urtti
Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties
published pages: 1446-1457, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.02.001
Drug Discovery Today 24/8 2020-04-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EYETREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EYETREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

E-CLIPS (2019)

Effects of Cross-Linguistic Interactions on Perception of Speech

Read More  

INSPiRE (2018)

The Influence of Information Search on Preference Formation and Choice

Read More